Reviewing Virax Biolabs Group (NASDAQ:VRAX) and Assure (OTCMKTS:IONM)

Virax Biolabs Group (NASDAQ:VRAX – Get Free Report) and Assure (OTCMKTS:IONM – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Virax Biolabs Group and Assure, as reported by MarketBeat.

Virax Biolabs Group presently has a consensus price target of $25.00, suggesting a potential upside of 771.08%. Given Virax Biolabs Group’s stronger consensus rating and higher possible upside, equities analysts plainly believe Virax Biolabs Group is more favorable than Assure.

Insider & Institutional Ownership

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 3.3% of Assure shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 3.8% of Assure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Virax Biolabs Group has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, Assure has a beta of 198.38, indicating that its stock price is 19,738% more volatile than the S&P 500.

Profitability

This table compares Virax Biolabs Group and Assure’s net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Virax Biolabs Group and Assure”s gross revenue, earnings per share and valuation.

Virax Biolabs Group has higher earnings, but lower revenue than Assure.

Summary

Virax Biolabs Group beats Assure on 7 of the 9 factors compared between the two stocks.

About Virax Biolabs Group

(Get Free Report)

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

About Assure

(Get Free Report)

Assure Holdings Corp., through its subsidiaries, provides technical and professional intraoperative neuromonitoring surgical support services in the United States. It offers services in the areas of neurosurgery, spine, cardiovascular, orthopedic, ear, nose, throat, and other surgical procedures. The company delivers various clinical and operational services, including scheduling of the interoperative neurophysiologist and supervising practitioner, real time monitoring, patient advocacy, and billing services to support surgeons and medical facilities during invasive procedures. Assure Holdings Corp. is based in Englewood, Colorado.